July 29, 2019 / 9:22 PM / in 20 days

Amgen bid to stop Neulasta biosimilar fails at Fed Circuit

Amgen Inc on Monday lost a bid to revive a lawsuit it filed seeking to block Coherus BioSciences Inc from selling a biosimilar version of its blockbuster chemotherapy drug Neulasta.

A three-judge panel of the U.S. Court of Appeals for the Federal Circuit affirmed a 2018 decision from a Delaware judge that dismissed Amgen’s case.

To read the full story on WestlawNext Practitioner Insights, click here: bit.ly/2KaVjRd

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below